Ford has teamed up with gig-economy start-up Postmates to develop its autonomous vehicle technology.
Ford’s VP of autonomous vehicles and electrification told Cheddar he hopes to learn exactly how self-driving cars can be used.
“We’re going to learn how the different forms of things that are being delivered work with AVs,” Sherif Marakby said. “Maybe some things work perfectly with autonomous vehicles, maybe some things don’t.”
Postmates offers on-demand delivery from small businesses to area residents. The company says it operates in over 250 cities and makes about 2.5 deliveries per month.
Ford is one of several car makers looking to use self-driving cars as a service.
Volkswagen and Hyundai recently announced a partnership with Aurora, an autonomous technology start-up, to roll out self driving vehicles.
For full interview [click Here](https://cheddar.com/videos/fords-smart-vehicle-smart-world).
Conditions have been mostly nice for travelers flying ahead of and on Christmas Day, but some naughty disruptions plagued those flying with Southwest Airlines again this year.
Gift cards make great stocking stuffers — just as long as you don't stuff them in a drawer and forget about them after the holidays.
Big Business This Week is a guided tour through the biggest market stories of the week, from winning stocks to brutal dips to the facts and forecasts generating buzz on Wall Street.
Bristol Myers Squibb agreed to buy schizophrenia drug maker Karuna Therapeutics in a $14 billion deal.
Supermarket chain Ralphs is facing a new lawsuit from the state of California.
Shake Shack is giving out free fried chicken sandwiches, bacon cheese fries and milkshakes nationwide.
The IRS is announcing a voluntary disclosure program.
Lionsgate announced its studio division is going to spin off in a merger with Screaming Eagle Acquisition Corp., which is a special purpose acquisition company.
A new report suggests that it's getting more difficult for an average American to afford a home.
The Food and Drug Administration warned consumers about a copycat version of the diabetes drug Ozempic.
